Administration, Inhalation

"Administration, Inhalation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.

Descriptor ID	D000280
MeSH Number(s)	E02.319.267.050
Concept/Terms	Administration, Inhalation Administration, Inhalation Drug Administration, Respiratory Administration, Respiratory Drug Respiratory Drug Administration Inhalation Drug Administration Drug Administration, Inhalation Administration, Inhalation Drug Inhalation Administration Drug Aerosol Therapy Drug Aerosol Therapy Aerosol Therapy, Drug Therapy, Drug Aerosol Drug Therapy, Aerosol Aerosol Drug Therapy Therapy, Aerosol Drug Inhalation of Drugs Inhalation of Drugs

Below are MeSH descriptors whose meaning is more general than "Administration, Inhalation".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Drug Administration Routes [E02.319.267]
Administration, Inhalation [E02.319.267.050]

Below are MeSH descriptors whose meaning is related to "Administration, Inhalation".

Below are MeSH descriptors whose meaning is more specific than "Administration, Inhalation".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Administration, Inhalation" by people in this website by year, and whether "Administration, Inhalation" was a major or minor topic of these publications.

Bar chart showing 132 publications over 28 distinct years, with a maximum of 15 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1997	0	2	2
1998	0	2	2
1999	0	2	2
2000	0	3	3
2001	0	1	1
2002	0	2	2
2004	0	3	3
2006	0	5	5
2007	0	2	2
2008	0	4	4
2009	0	6	6
2010	1	5	6
2011	0	7	7
2012	0	7	7
2013	0	2	2
2014	0	3	3
2015	1	4	5
2016	0	6	6
2017	0	8	8
2018	1	7	8
2019	0	9	9
2020	0	15	15
2021	0	6	6
2022	0	11	11
2023	0	2	2
2024	0	2	2
2025	0	2	2

Below are the most recent publications written about "Administration, Inhalation" by people in Profiles.

Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, Bourbeau J, Korn S, Bafadhel M, Han MK, Kolterer S, Miller K, Mouneimne D, Fletcher J, Mayer B, Min J, Pavord ID. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. N Engl J Med. 2025 May 01; 392(17):1710-1720.

View in: PubMed
Singh D, Martinez FJ, Hurst JR, Han MK, Gale CP, Fredriksson M, Kisielewicz D, Mushunje A, Movitz C, Ojili N, Parikh H, Arya N, Bowen K, Patel M. Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS). Am J Respir Crit Care Med. 2025 Feb; 211(2):205-214.

View in: PubMed
Quezada WA, Angulo D, Murray S, Joo M, Han M, Make B, Thomashow B, Mannino D, Tapp H, Martinez F, Yawn BP. Exacerbation-like events in the 12 months prior to identification of chronic respiratory conditions in a primary care population. Respir Med. 2024 09; 231:107695.

View in: PubMed
Kiani S. Inhaled Oral Flecainide for Rapid Cardioversion of Atrial Fibrillation. JACC Clin Electrophysiol. 2024 Jun; 10(6):1034-1036.

View in: PubMed
Rabe KF, Rennard S, Martinez FJ, Celli BR, Singh D, Papi A, Bafadhel M, Heble J, Radwan A, Soler X, Jacob Nara JA, Deniz Y, Rowe PJ. Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook. Am J Respir Crit Care Med. 2023 08 15; 208(4):395-405.

View in: PubMed
Archontakis Barakakis P, Tran T, You JY, Hernandez Romero GJ, Gidwani V, Martinez FJ, Fortis S. High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2023; 18:469-482.

View in: PubMed
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P. Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022; 17:3061-3073.

View in: PubMed
Bardsley S, Criner GJ, Halpin DMG, Han MK, Hanania NA, Hill D, Lange P, Lipson DA, Martinez FJ, Midwinter D, Siler TM, Singh D, Wise RA, van Zyl-Smit RN, Berkman N. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med. 2022 12; 205:107040.

View in: PubMed
LeMaster WB, Quibrera PM, Couper D, Tashkin DP, Bleecker ER, Doerschuk CM, Ortega VE, Cooper C, Han MK, Woodruff PG, O'Neal WK, Anderson WH, Alexis NE, Bowler RP, Barr RG, Kaner RJ, Dransfield MT, Paine R, Kim V, Curtis JL, Martinez FJ, Hastie AT, Barjaktarevic I. Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort. Chest. 2023 03; 163(3):515-528.

View in: PubMed
Herrmann Z, Jaini P, Hsu J, Rush AJ. Two Cases Comparing the Presentations and Outcomes of Heroin-induced Toxic Leukoencephalopathy. J Psychiatr Pract. 2022 09 01; 28(5):426-430.

View in: PubMed

People

Explore

Similar Concepts

Top Journals